FOLH1 and metastatic malignant neoplasm: While genomic correlates of PSMA and FDG expression to clinical outcomes are limited, it is expected that genomic and phenotypic heterogeneity may account for variable treatment response as observed in molecular, or genetic, analyses for both localised and metastatic cancers [38].